NATCO receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA®) ANDA in the US market

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that its marketing and distribution partner Alvogen Pine Brook LLC, has received tentative approval for our Abbreviated New Drug Application (ANDA) for Ibrutinib Tablets 560mg, 420mg, 280mg and 140mg strengths (generic for IMBRUVICA®), from the U.S. Food and Drug Administration (USFDA).

Based on our ANDA filing date and the approval timeline, NATCO believes that we are eligible for 180 days of sole generic marketing exclusivity for all the strengths of the tablet dosage form of the product at the time of launch.

As per industry sales data, IMBRUVICA® (Tablet and Capsule dosage forms) had generated annual sales of $3.7 billion during the twelve months period ending December 2020 in the US market, of this, all the strengths of IMBRUVICA® Tablets alone generated sales of $3.0 billion during the same period.

*All brand names and trademarks are the property of their respective owners.

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.917.8 as compared to the previous close of Rs. 907.9. The total number of shares traded during the day was 31175 in over 1667 trades.

The stock hit an intraday high of Rs. 932.5 and intraday low of 888.1. The net turnover during the day was Rs. 28424038.

Source : Equity Bulls

Keywords